These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15819288)

  • 1. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Delaunoit T; Rubin J; Neczyporenko F; Erlichman C; Hobday TJ
    Mayo Clin Proc; 2005 Apr; 80(4):502-6. PubMed ID: 15819288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
    Khagi S; Saif MW
    JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
    Khagi S; Saif MW
    JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Boucher JE; Sommers R
    Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
    Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
    Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
    Janson ET
    J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Chandrasekharan C
    Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours.
    Oberg K
    Digestion; 1996; 57 Suppl 1():81-3. PubMed ID: 8813477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Modlin I
    Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
    Hansen CP; Knigge U
    Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.